NRT had the foresight to get listed as NVGN on the Nasdaq as well (ADR's). That immediately put it on the US radar.
It took a while to mop up the free-floating shares (NRT), but after some 45% disappeared to the US, the pressure started to amount and the NRT share price rose.
There is little freefloat now and the US as well as Aussies are waiting for some clinical results.
Capital and financial management is superb and I would rate it #1 in this repect on the Biotech List, closely followed by NAL.
Gerry Bought NRT for $1.75 at end of Oct 2002, now about $6.50-$6.60. It is of course on the Biotech list.
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Held
